DE69622386T2 - Synergistische kombinationen von zidovudine, 1592u89 und 3tc - Google Patents

Synergistische kombinationen von zidovudine, 1592u89 und 3tc

Info

Publication number
DE69622386T2
DE69622386T2 DE69622386T DE69622386T DE69622386T2 DE 69622386 T2 DE69622386 T2 DE 69622386T2 DE 69622386 T DE69622386 T DE 69622386T DE 69622386 T DE69622386 T DE 69622386T DE 69622386 T2 DE69622386 T2 DE 69622386T2
Authority
DE
Germany
Prior art keywords
cis
amino
zidovudine
oxathiolan
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69622386T
Other languages
German (de)
English (en)
Other versions
DE69622386D1 (de
DE122005000029I2 (de
Inventor
Walter Barry
Heider St. Clair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69622386(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE69622386D1 publication Critical patent/DE69622386D1/de
Application granted granted Critical
Publication of DE69622386T2 publication Critical patent/DE69622386T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
DE69622386T 1995-03-30 1996-03-28 Synergistische kombinationen von zidovudine, 1592u89 und 3tc Expired - Lifetime DE69622386T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
DE69622386D1 DE69622386D1 (de) 2002-08-22
DE69622386T2 true DE69622386T2 (de) 2003-02-13

Family

ID=26306774

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69622386T Expired - Lifetime DE69622386T2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von zidovudine, 1592u89 und 3tc
DE200512000029 Pending DE122005000029I1 (de) 1995-03-30 1996-03-28 Synergistische Kombinationen von Zidovudine, 1592u89 und 3tc.
DE1996622386 Active DE122005000029I2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von Zidovudine, 1592u89 und 3TC

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE200512000029 Pending DE122005000029I1 (de) 1995-03-30 1996-03-28 Synergistische Kombinationen von Zidovudine, 1592u89 und 3tc.
DE1996622386 Active DE122005000029I2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von Zidovudine, 1592u89 und 3TC

Country Status (35)

Country Link
US (1) US6417191B1 (enExample)
EP (1) EP0817637B1 (enExample)
JP (1) JP2954357B2 (enExample)
KR (1) KR100542536B1 (enExample)
CN (1) CN1103593C (enExample)
AP (1) AP652A (enExample)
AT (1) ATE220551T1 (enExample)
AU (1) AU715213B2 (enExample)
BR (3) BRPI9607851B8 (enExample)
CA (1) CA2216634C (enExample)
CZ (1) CZ295940B6 (enExample)
DE (3) DE69622386T2 (enExample)
DK (1) DK0817637T3 (enExample)
EA (1) EA000626B3 (enExample)
EE (1) EE04047B1 (enExample)
ES (1) ES2179193T3 (enExample)
FR (1) FR05C0022I2 (enExample)
GE (1) GEP20022647B (enExample)
HU (1) HU224010B1 (enExample)
IL (1) IL117727A (enExample)
LU (1) LU91171I2 (enExample)
MX (1) MX9707316A (enExample)
MY (1) MY115461A (enExample)
NL (1) NL300195I2 (enExample)
NO (2) NO313787B1 (enExample)
NZ (1) NZ306419A (enExample)
OA (1) OA10616A (enExample)
PL (1) PL187085B1 (enExample)
PT (1) PT817637E (enExample)
RO (1) RO117995B1 (enExample)
SI (1) SI0817637T1 (enExample)
SK (1) SK283825B6 (enExample)
TR (1) TR199701074T1 (enExample)
UA (1) UA60293C2 (enExample)
WO (1) WO1996030025A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
CN118063537A (zh) 2015-09-08 2024-05-24 莫纳什大学 定向淋巴的前药
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
JP7810970B2 (ja) 2020-02-05 2026-02-04 シーポート・セラピューティクス・インコーポレイテッド 神経ステロイドの脂質プロドラッグ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ATE131730T1 (de) * 1991-05-16 1996-01-15 Glaxo Group Ltd Nukleosidanalogen enthaltende antiviren- zubereitungen
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
KR20000022226A (ko) 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
CA2262765A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CZ309097A3 (cs) 1998-05-13
BRPI9607851B8 (pt) 2019-11-05
HK1009401A1 (en) 1999-09-10
LU91171I2 (fr) 2005-07-04
DK0817637T3 (da) 2002-11-11
MY115461A (en) 2003-06-30
EA000626B3 (ru) 2016-04-29
NL300195I2 (nl) 2005-11-01
EE9700240A (et) 1998-04-15
IL117727A0 (en) 1996-07-23
MX9707316A (es) 1997-11-29
ES2179193T3 (es) 2003-01-16
CA2216634A1 (en) 1996-10-03
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
JP2954357B2 (ja) 1999-09-27
HU224010B1 (hu) 2005-04-28
SI0817637T1 (en) 2002-10-31
AP652A (en) 1998-06-19
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
NO2005014I2 (no) 2008-02-11
LU91171I9 (enExample) 2018-12-28
PL187085B1 (pl) 2004-05-31
BR9607851B1 (pt) 2009-01-13
RO117995B1 (ro) 2002-12-30
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
FR05C0022I2 (enExample) 2005-10-21
KR100542536B1 (ko) 2006-03-23
ATE220551T1 (de) 2002-08-15
KR19980703420A (ko) 1998-11-05
US6417191B1 (en) 2002-07-09
CA2216634C (en) 2004-07-20
BR9607851A (pt) 1998-07-21
SK129597A3 (en) 1998-07-08
NO313787B1 (no) 2002-12-02
DE122005000029I1 (de) 2005-10-06
IL117727A (en) 1999-11-30
OA10616A (en) 2001-03-15
CZ295940B6 (cs) 2005-12-14
EE04047B1 (et) 2003-06-16
NO2005014I1 (no) 2005-06-06
BRPI9612992B1 (pt) 2020-08-04
EA199700203A1 (ru) 1998-02-26
FR05C0022I1 (enExample) 2005-06-10
CN1103593C (zh) 2003-03-26
HUP9801571A3 (en) 2001-04-28
EA000626B1 (ru) 1999-12-29
DE122005000029I2 (de) 2006-04-27
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
CN1185110A (zh) 1998-06-17
AU5497296A (en) 1996-10-16
UA60293C2 (uk) 2003-10-15
NO974510D0 (no) 1997-09-29
JPH10511682A (ja) 1998-11-10
NO974510L (no) 1997-09-29
EP0817637B1 (en) 2002-07-17
AU715213B2 (en) 2000-01-20
PL322532A1 (en) 1998-02-02
EP0817637A1 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
AU715213B2 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC or FTC
DE69230140T2 (de) Antivirale nucleosidkombination
DE3650741T2 (de) Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
DE3687069T2 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE69313872T2 (de) Verbindung von nucleocidanaloga zur behandlung viraler infektionen
DE69727240T2 (de) Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
DE69527294T2 (de) 4-[2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl]-2-cyclopenten-1-methanol-succinat als antivirales mittel
DE69918447T2 (de) Antivirale kombinationen von lamivudin und adefovir
DE69912842T2 (de) Antivirale nukleosidanaloga
DE69718168T2 (de) Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE60012961T2 (de) Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion
DE3780343T2 (de) Antivirale 8-phenylxanthine.
DE69326548T2 (de) Therapeutische kombinationen
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
AU8017298A (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
HK1035670B (en) Antiviral combinations of lamivudine and adefovir
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of

Legal Events

Date Code Title Description
R008 Case pending at federal patent court

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R039 Revocation action filed

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R431 Request for term correction

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R040 Withdrawal/refusal of revocation action now final

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R432 Decision on term correction now final

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222